 |
 |
Date Announced: 18 May 2011
High-tech drug delivery and anti-wrinkle treatment set for global deployment.
SAN JOSE, Calif., May 18, 2011 /PRNewswire/ -- Oclaro, Inc. (NASDAQ:OCLR - News), a tier-one provider of optical communications and laser solutions, today announced that its 9xx nm high-power laser diode bars have been selected by Pantec Biosolutions, the leading provider of epidermal medical applications, for use in its next generation P.L.E.A.S.E.® (Precise Laser Epidermal System) platform. This cutting-edge new laser platform represents a new era in biomedical applications by enabling an easy, painless and needle-free delivery method for drugs, as well as safe tissue ablation for skin rejuvenation.
According to Pantec, the global aesthetic market, which includes tissue ablation, is expected to grow from a $4.4 billion market in 2010 to a $7.5 billion market in 2015; while the market for transdermal drug delivery is growing rapidly and is expected to be a multi-billion dollar market by 2015. Designed for medical professionals and consumers, these new devices offer a pain-free delivery method for a variety of medical applications, such as in-vitro fertilization, vaccinations and wrinkle removal. Oclaro worked closely with Pantec to deliver a customized quasi continuous wave (QCW) sub-assembly laser diode solution that delivered the performance and reliability needed, at a price point that will enable wide-spread adoption in the consumer space. Pantec's first Oclaro-based product, which is called the P.L.E.A.S.E.® Professional, is a tabletop system that will be used for both transdermal delivery and tissue ablation. This device will initially be sold in Europe with plans to bring the product into selected markets worldwide, starting in 2011.
"This win with Pantec is yet another example of how lasers have reached the price/performance targets that enable them to be widely used in the high-volume consumer space," said Gunnar Stolze, Worldwide Sales Director of Industrial and Consumer Lasers at Oclaro. "The combination of Pantec's P.L.E.A.S.E. platform technology with Oclaro's highly-efficient, high-volume manufacturing capabilities can deliver innovation to the consumer that revolutionizes modern day medical and cosmetic procedures such as drug delivery and tissue ablation."
"We partnered with Oclaro because it delivered the technology and reliable manufacturing excellence we needed, and also worked closely with us to design the best solution for our next generation P.L.E.A.S.E.® products," said Thomas Bragagna, CTO at Pantec Biosolutions. "As this market continues to expand, we are confident that only a world-class supplier such as Oclaro will enable us to establish a clear leadership position in a space that is poised for explosive growth in the future."
Source: Oclaro
E-mail: via web site
Web Site: www.oclaro.com
| © 2024 SPIE Europe |
|
